(CPG Brain) Why Unilever consumer health pivot is going to be expensive

 










Our last article on the Anglo Dutch consumer goods giant Unilever spoke to the rising costs of ethical ambition through its subsidiary Ben and Jerry’s decision exit the occupied territories and pain in the neck you know what storm that followed. However, the costs of Unilever’s ethical ambitions are nothing compared to the costs the company are going to incur pivoting away from food to consumer health. 


While Unilever ambition to move towards consumer health make sense and may prove to be shrewd decision down the line, the speed the company is moving is concerning both investors and more importantly rating shops. Unilever proposes to make this pivot through selling its food brands and using the proceeds to acquire consumer health assets which is all well and good but we, investors and ratings shops find it hard to believe they can make this pivot without taking on a lot of debt. Fitch came and publicly warned Unilever that its aggressive consumer health through an acquisition of Glaxo Smith Kline’s and Pfizer’s consumer health business could lead to credit downgrade effectively costing them their A+ credit rating. 


The consequence of a credit downgrade is that would mean Unilever will have borrow money at higher rates which may constrict which projects Unilever can pursue (oh that’s why there selling their food business). Used to borrow at low rates, Unilever may have to pursue riskier projects due to a higher hurdle rate which could affect Unilever’s valuation. 


However, given how fast Unilever are moving and how aggressive they pursued a deal for GSK’S consumer health business, it looks like they’ve taken that downgrade into account. Like many of us, the pandemic forced people to look at their lives and the same applied to businesses, Unilever took a look at its business and (especially food) brands saw plenty it didn’t like. Whether it’s soaring food prices, thin margins or the newsworthy sketchy supply chains that put them at odds with their ethical ambitions (can’t fight for equality when exploitation is rampant throughout your supply chains), Unilever resolve to move out the food business rock solid. With inflation soaring, it would sense to slow down as has enough pricing power to pass on procurement costs to consumers however Unilever seem to be of the opinion that rising costs could see consumers use cheaper discounted brands to ease the pressure on their pocketbooks. 


Whatever the case, Unilever are dead set on becoming a consumer health goods monster come hell or high water, credit downgrades be damned. Like we’ve mentioned, this isn't the worse move as the margins are better and the headlines are less embarrassing (no international political debacles when you leave a market for instance) however this pivot will be a painful and may lead to dismissals if even look like it won’t work (Alan Jope were looking at you) but with consumer health being a more stable business, it's only a matter of time before any tumult its share price or performance corrects itself. 


In sum, Unilever’s move away from its food business and the baggage that comes with it makes sense but the speed and aggressiveness the company it’s making transition at is concerning as trying to get an oil tanker to move as quick as a speedboat has disaster written all over it. 

Comments

Popular posts from this blog

(CPG Brain) Consumer staples and pricing power: a love affair gone sour?

(CPG Brain) Unilever: the battle of Unilever 2021/22 is over but the war has begun.

How to beat up on your suppliers - a Walmart masterclass